Metabolomics of patients with CAD and CKD

The morbidity and mortality of global Coronary artery disease (CAD) and chronic kidney disease (CKD) have continued to rise. Recent studies highlight that gut microbiome and their metabolites contribute to heart-kidney cross-talk.To better understand the enrichment and functional changes associated with microbiome-derived metabolites.We enrolled patients with CAD and CKD and untargeted metabolomics analysis was conducted on patient serum samples.We revealed many distinct metabolites and underscored significant differences in metabolites between the two groups.Thus, our data provides novel insights into regulation of metabolic function in patients with CAD and CKD and informs current efforts to bring metabolites predictive factors into clinical application.